News Search Results
Mar 09, 2026, 11:07 ET PrimeC Long-Term Survival Data to Be Presented at a Leading ALS Scientific Conference
NeuroSense Therapeutics Ltd. (NASDAQ: NRSN) ("NeuroSense"), a late-stage clinical biotechnology company focused on developing disease-modifying treatments for neurodegenerative diseases, today announced that the recently reported long-term
More news about: NeuroSense
Mar 09, 2026, 11:01 ET CSL announces expansion of Illinois plasma therapy manufacturing facility
the critical role Illinois plays in producing the life-saving therapies patients depend on," said John Conrad, President and CEO of the Illinois Biotechnology Innovation Organization (iBIO). "Our state's combination of scientific talent, manufacturing expertise, and leading research institutions makes
More news about: CSL
Mar 09, 2026, 10:50 ET CNS Drug Developers Add Pharma Veterans as Sector Nears First FDA Decisions
for treatment-resistant depression, enrolling 142 patients. AtaiBeckley recently redomiciled to the United States, was added to the NASDAQ Biotechnology Index, and reports a cash runway extending into 2029, providing financial stability through multiple anticipated clinical catalysts.Definium
More news about: USA News Group
Mar 09, 2026, 08:30 ET Anixa Biosciences Receives Notice of Allowance from Korean Ministry of Intellectual Property (MOIP) for Patent Covering Breast Cancer Vaccine Technology
Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer, today announced that the Korean Ministry of Intellectual Property (MOIP) has issued a
More news about: Anixa Biosciences, Inc.
Mar 09, 2026, 08:05 ET INOVIO to Participate in Upcoming Scientific Conferences
PLYMOUTH MEETING, Pa., March 9, 2026 /PRNewswire/ -- INOVIO (NASDAQ:INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-associated diseases, cancer and infectious
More news about: INOVIO Pharmaceuticals, Inc.
Mar 09, 2026, 07:30 ET ImmunityBio Announces Resubmission of Supplemental BLA to the FDA for ANKTIVA® Plus BCG in BCG-Unresponsive NMIBC with Papillary Disease Following Agency Review of Additional Data
https://pmc.ncbi.nlm.nih.gov/articles/PMC3357503/#:~:text=Among%20NMIBCs%2C%20around%2070%25%20present,NMIBC%20and%20often%20go%20underutilized.About ImmunityBio ImmunityBio, Inc. is a biotechnology company focused on innovating, developing, and commercializing next-generation immunotherapies designed to activate the patient's immune system
More news about: ImmunityBio
Mar 09, 2026, 06:00 ET Astro Pak Appoints Kyle Campbell as Senior Vice President of Field Services
LLCAstro Pak LLC is a leading provider of high purity and precision cleaning services, serving critical industries such as pharmaceutical, biotechnology, food & beverage, datacenters, semiconductor, aerospace & defense, and more. Founded in 1959, Astro Pak is committed to ensuring the highest
More news about: Astro Pak
Mar 09, 2026, 02:28 ET Leads Biolabs' Opamtistomig (LBL-024) Enrolls First ESCC Patient, Exploring Dual PD-L1/4-1BB Mechanism for Superior Survival Benefits in China's High-Incidence Cancer
potential as a broad-spectrum immuno-oncology therapy.About Leads BiolabsFounded in 2012, Leads Biolabs is a clinical-stage biotechnology company dedicated to the discovery, development, and commercialization of innovative therapies to address underserved medical needs in oncology,
More news about: Leads Biolabs
Mar 08, 2026, 22:25 ET LOTTE Biologics to Participate in DCAT Week 2026 in New York to Explore Global Partnership Opportunities
March 9, 2026 /PRNewswire/ -- LOTTE Biologics announced today that it will participate in DCAT Week 2026, a global pharmaceutical and biotechnology industry event taking place in New York from March 23 to 26, to explore new partnership opportunities and strengthen its global presence in the
More news about: Lotte Biologics
Mar 07, 2026, 11:45 ET Kessler Topaz Meltzer & Check, LLP Filed a Securities Fraud Class Action Lawsuit Against uniQure N.V. (QURE); April 13, 2026, Lead Plaintiff Deadline
(short video)UNIQURE N.V. CLASS ACTION LAWSUIT - COMPLAINT ALLEGATION SUMMARY:uniQure is a biotechnology company developing gene therapies for rare diseases, including Huntington's disease (HD). uniQure's leading drug candidate is AMT-130, a novel gene
More news about: Kessler Topaz Meltzer & Check, LLP
Mar 07, 2026, 09:00 ET The 15th Five-Year Plan featuring opening up: China and the world sharing the future
open more sectors, particularly the service industry. Pilot opening-up programs will be broadened in fields such as value-added telecom services, biotechnology and wholly foreign-owned hospitals. The negative list for cross-border trade in services will be further shortened. National treatment for foreign-invested
More news about: China.org.cn
Mar 06, 2026, 18:00 ET Nektar Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
conditions of the stock option agreement covering the grant.About Nektar TherapeuticsNektar Therapeutics is a clinical-stage biotechnology company focused on developing treatments that address the underlying immunological dysfunction in autoimmune and chronic inflammatory diseases.
More news about: Nektar Therapeutics
Mar 06, 2026, 17:37 ET AdvisorShares Announces NAV Restatement for the AdvisorShares MSOS Daily Leveraged ETF (MSOX)
regulations related to environmental protection, health and safety. Cannabis-related companies may also be subject to risks associated with the biotechnology and pharmaceutical industries. These risks include increased government regulation, the use and enforcement of intellectual property rights and
More news about: AdvisorShares
Mar 06, 2026, 08:00 ET U.S. FDA Approves TECVAYLI® in Combination with DARZALEX FASPRO® for Relapsed/Refractory Multiple Myeloma
than one million patient lives through ten commercialized products across over 100 global markets and is licensed to leading pharmaceutical and biotechnology companies including Roche, Takeda, Pfizer, Janssen, AbbVie, Eli Lilly, Bristol-Myers Squibb, argenx, ViiV Healthcare, Chugai Pharmaceutical, Acumen
More news about: Halozyme Therapeutics, Inc.
Mar 06, 2026, 07:47 ET Intensity Therapeutics Regains Compliance with Nasdaq's Minimum Bid Price Requirement
March 6, 2026 /PRNewswire/ -- Intensity Therapeutics, Inc. ("Intensity" or "the Company") (Nasdaq: INTS), a late-stage clinical biotechnology company focused on the discovery and development of novel intratumoral cancer therapies that are designed to kill tumors and increase immune system
More news about: Intensity Therapeutics Inc.
Mar 06, 2026, 05:53 ET Insilico and TaiGen Achieve Milestone in Collaboration: Out-Licensed CKD Anemia Candidate ISM4808 Completes first human enrollment and dosing in Phase I clinical trial
Medicine, HKEX: 03696), a clinical-stage biotechnology company powered by generative artificial intelligence (AI), announced that ISM4808, an AI-driven PHD inhibitor for chronic kidney disease (CKD)-related anemia previously out-licensed to TaiGen Biotechnology (TaiGen*-KY, 4157), has achieved its first
More news about: Insilico Medicine
Mar 06, 2026, 04:42 ET Lupin Ranks No. 1 Globally in Pharma; Tops All Sectors in India in S&P ESG Assessment 2025
products distributed in over 100 markets. Lupin specializes in pharmaceutical products, including branded and generic formulations, complex generics, biotechnology products, and active pharmaceutical ingredients. Trusted by healthcare professionals and consumers globally, the company enjoys a strong position
More news about: Lupin Limited
Mar 05, 2026, 23:38 ET Exosome Diagnostic and Therapeutics Market to Reach USD 401.70 Million by 2032 Amid Rapid Advances in Liquid Biopsy, Precision Medicine, and Exosome-Based Drug Delivery - Credence Research
diagnostic and therapeutics market, accounting for approximately 42% of global revenue. The region's dominance is supported by strong investments in biotechnology, the presence of advanced research institutions, early adoption of innovative diagnostic technologies, and high demand for precision medicine solutions.
More news about: Credence Research Inc.
Mar 05, 2026, 16:57 ET Pomerantz Law Firm Announces the Filing of a Class Action Against Inovio Pharmaceuticals, Inc. and Certain Officers - INO
[Click here for information about joining the class action]Inovio is a biotechnology company focused on the discovery, development, and commercialization of DNA medicines to treat and protect people from diseases associated with,
More news about: Pomerantz LLP
Mar 05, 2026, 16:05 ET INOVIO to Report Fourth Quarter and Full Year 2025 Financial Results on March 12, 2026
PLYMOUTH MEETING, Pa., March 5, 2026 /PRNewswire/ -- INOVIO (NASDAQ:INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-associated diseases, cancers, and infectious
More news about: INOVIO Pharmaceuticals, Inc.
Mar 05, 2026, 16:01 ET AMGEN TO PRESENT AT THE LEERINK PARTNERS 2026 GLOBAL HEALTHCARE CONFERENCE
best of biology and technology, Amgen reaches millions of patients with its medicines. More than 45 years ago, Amgen helped establish the biotechnology industry at its U.S. headquarters in Thousand Oaks, California, and it remains at the cutting edge of innovation, using technology and human genetic
More news about: Amgen
Mar 05, 2026, 12:19 ET Rubin Rudman Launches New Hospitality Law Practice Group
Rubin Rudman serves national and international companies, including large public companies and closely held businesses; real estate developers; biotechnology, pharmaceutical and medical device makers; hospitality companies; regulated industries, public entities and municipalities; insurance companies
More news about: Rubin Rudman
Mar 05, 2026, 11:16 ET Cultured Meat Market to Reach $6,501.8 million, Globally, by 2033 at 58.5% CAGR: Allied Market Research
environmental and animal welfare concerns, and continuous advancements in cellular agriculture technologies. In addition, expanding investments in food biotechnology, improvements in bioreactor and growth media development, and growing consumer interest in clean-label products are strengthening market demand.
More news about: Allied Market Research
Mar 05, 2026, 10:16 ET Lipid Nanoparticles Market to Reach $3.1 Billion, Globally, by 2033 at 13.1% CAGR: Allied Market Research
https://www.alliedmarketresearch.com/connect-to-analyst/A323703 By end user, the pharmaceutical & biotechnology companies segment held the highest market share in 2023Pharmaceutical and biotechnology companies accounted for the largest share in 2023, supported by the increasing development and
More news about: Allied Market Research
Mar 05, 2026, 10:14 ET BIOMEMORY ACQUIRES THE ASSETS OF CATALOG, BOOSTING ITS AMBITIONS IN DNA DATA STORAGE AND COMPUTING
years of research work in Sorbonne University and CNRS French national labs. It is a leading innovator and market player, at the intersection of biotechnology and information technologies. The company develops IT-friendly Data Storage and cybersecurity solutions, using DNA as the storage media. Solutions
More news about: Biomemory